Intellia Therapeutics, Inc.
NGM: NTLALive Quote
📈 ZcoreAI Score
Our AI model analyzes Intellia Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NTLA Z-Score →About Intellia Therapeutics, Inc.
Healthcare
Biotechnology
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Intellia Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 78.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -53.5%, which indicates that capital utilization is currently under pressure.
At a current price of $13.49, NTLA currently sits at the 31st percentile of its 52-week range (Range: $6.73 - $28.25).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.59B
Trailing P/E
--
Forward P/E
-4.62
Beta (5Y)
1.99
52W High
$28.25
52W Low
$6.73
Avg Volume
4.46M
Day High
Day Low